Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptimICE-PCR
NCT05812807Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2023
- Primary completion
- May 2033
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Arm I (pembrolizumab) with Arm II (observation) (2 arms). Primary endpoints: Recurrence-free survival at 10 years, Quality of life at 27 weeks and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05812807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812807.